Abstract
Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane.
Keywords: Capecitabine, chemotherapy, docetaxel, MBC, nab-paclitaxel, paclitaxel.
Current Cancer Drug Targets
Title:Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile
Volume: 16 Issue: 5
Author(s): José Ángel García-Sáenz, Miguel Martín, Pilar Zamora, Ignasi Tusquets, Miguel Ángel Seguí, Ana Santaballa, Pedro Sánchez-Rovira, Manuel Ruiz, Álvaro Rodríguez-Lescure, Arrate Plazaola, Eduardo Martínez de Dueñas, Noelia Martínez-Jáñez, Guillermo López-Vivanco, Rafael López, Juan de la Haba, Antonio González-Martín, Andrés García-Palomo, Elena Galve, Lourdes Calvo, Norberto Batista, Agustí Barnadas, Francisco Ayala de la Peña, José Manuel Aramendía, Isabel Álvarez, Raquel Andrés, Ana Lluch, Antonio Llombart, Javier Cortés, Eva Ciruelos and Emilio Alba
Affiliation:
Keywords: Capecitabine, chemotherapy, docetaxel, MBC, nab-paclitaxel, paclitaxel.
Abstract: Around 40% of patients with breast cancer will present with a recurrence of the disease. Chemotherapy is recommended for patients with recurrent hormone-independent or hormone-refractory breast cancer and almost all patients with metastatic breast cancer (MBC) receive chemotherapy during their medical history. Nanoparticle albuminbound (nab)-paclitaxel is a solvent-free, 130-nanometer particle formulation of paclitaxel. Nab-paclitaxel can be administered to all patients for whom the treatment choice is a taxane. In this review, 6 patient profiles for which nabpaclitaxel may be particularly useful are described and analyzed: (i) as first-line treatment of MBC, (ii) as second-line treatment of MBC after oral chemotherapy, (iii) after a standard taxane, (iv) as third-line treatment after a standard taxane and oral chemotherapy, (v) for patients with HER2-positive MBC and (vi) for patients with intolerance to standard taxanes. Nab-paclitaxel is a rational treatment choice for patients with MBC in different settings, as well as for those with prior exposure to a standard taxane.
Export Options
About this article
Cite this article as:
Ángel García-Sáenz José, Martín Miguel, Zamora Pilar, Tusquets Ignasi, Ángel Seguí Miguel, Santaballa Ana, Sánchez-Rovira Pedro, Ruiz Manuel, Rodríguez-Lescure Álvaro, Plazaola Arrate, Martínez de Dueñas Eduardo, Martínez-Jáñez Noelia, López-Vivanco Guillermo, López Rafael, de la Haba Juan, González-Martín Antonio, García-Palomo Andrés, Galve Elena, Calvo Lourdes, Batista Norberto, Barnadas Agustí, Ayala de la Peña Francisco, Manuel Aramendía José, Álvarez Isabel, Andrés Raquel, Lluch Ana, Llombart Antonio, Cortés Javier, Ciruelos Eva and Alba Emilio, Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile, Current Cancer Drug Targets 2016; 16 (5) . https://dx.doi.org/10.2174/1568009615666150817121731
DOI https://dx.doi.org/10.2174/1568009615666150817121731 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticancer Activity of Bisphosphonates in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry A Review on Post-traumatic Stress Disorder (PTSD): Symptoms, Therapies and Recent Case Studies
Current Molecular Pharmacology Non-Invasive Cell Tracking in Cancer and Cancer Therapy
Current Topics in Medicinal Chemistry Cancer Stem Cell Model in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Current κ Opioid Receptor Ligands and Discovery of a New Molecular Scaffold as a κ Opioid Receptor Antagonist Using Pharmacophore-Based Virtual Screening
Current Pharmaceutical Design Oleic Acid Protects Against Oxidative Stress Exacerbated by Cytarabine and Doxorubicin in Rat Brain
Anti-Cancer Agents in Medicinal Chemistry Sao Paulo Research Conference on Molecular Medicine and Pharmacogenetics, A Joint Meeting with the IUPHAR Sub-Committee on Pharmacogenetics and the Brazilian Pharmacogenetics Network, Sao Paulo, Brazil, September 18-20, 2008
Current Pharmacogenomics and Personalized Medicine Facing the threat of Antifungal Resistance: Report from the 7th Trends in Medical Mycology (TIMM-7) 9-12 October 2015, Lisbon, Portugal
Anti-Infective Agents The Role of αA-Crystallin in Experimental Autoimmune Uveitis
Current Molecular Medicine The Intestinal Environment in Health and Disease – Recent Insights on the Potential of Intestinal Bacteria to Influence Human Health
Current Pharmaceutical Design Raman Spectroscopy-based Metabonomics of HIV-infected Sera Detects Amino Acid and Glutathione Changes
Current Metabolomics Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases
Current Drug Targets An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry Potential Cell Signalling Mechanisms Involved in Differential Placental Angiogenesis in Mild and Severe Pre-Eclampsia
Current Vascular Pharmacology Adjuvant and Neoadjuvant Chemotherapy for Soft Tissue Sarcomas
Current Medicinal Chemistry Natural Aristolochia Alkaloid Aristololactam-β-D-glucoside: Interaction with Biomacromolecules and Correlation to the Biological Perspectives
Mini-Reviews in Medicinal Chemistry Network Medicine and High Throughput Screening
Current Drug Discovery Technologies Radiolabelled Molecules for Imaging the Translocator Protein (18 kDa) Using Positron Emission Tomography
Current Medicinal Chemistry Trends in Biotechnological Drugs for Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Postmenopausal Persistent Unilocular Ovarian Formations are not Risk Factor for Ovarian Carcinoma. A Long-Term Follow-Up Cohort Study
Current Women`s Health Reviews